Physician profile
Daniel S Selig
NPI 1770755480
$3,569.13
in general payments reported to CMS, 2019-2025
26 companies · $625 in 2025
The $625 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $181 · 2021: $475 · 2022: $828 · 2023: $779 · 2024: $544 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $546.55 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $539.23 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $505.78 | 2021-2023 | Qelbree |
| Collegium Pharmaceutical, INC. | $322.59 | 2025 | Jornay Pm |
| Pfizer INC. | $317.11 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $245.29 | 2019-2022 | |
| Glaxosmithkline, LLC. | $132.06 | 2021-2024 | Bexsero, Rotarix |
| Merck Sharp & Dohme LLC | $129.20 | 2020-2024 | M-M-R II, Gardasil 9, Vaxneuvance |
| Revance Therapeutics, INC. | $125.00 | 2025 | Daxxify |
| Kaleo, INC. | $113.82 | 2019-2020 | |
| Sanofi Pasteur INC. | $105.23 | 2020-2025 | |
| Allergan, INC. | $94.95 | 2022 | |
| Sanofi-Aventis U.S. LLC | $71.92 | 2025 | |
| Galderma Laboratories, L.P. | $52.95 | 2021-2023 | |
| Sobi, INC | $44.82 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $39.67 | 2020 | |
| Abbvie INC. | $26.70 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.70 | 2024 | Flumist Quadrivalent |
| Hologic Sales and Service, LLC | $22.07 | 2025 | Aptima |
| Ultragenyx Pharmaceutical INC. | $20.35 | 2024 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.66 | 2025 | |
| Seqirus USA INC | $17.46 | 2023 | Flucelvax Quadrivalent |
| Kowa Pharmaceuticals America, INC. | $15.25 | 2025 | Zoryve |
| Mannkind Corporation | $13.81 | 2021 | |
| Adlon Therapeutics L.P. | $13.47 | 2020 | |
| Phadia US INC. | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Selig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.